Post-operative KEloids iRradiation (POKER): does the surgery/high-dose interventional radiotherapy association make a winning hand?

Brachytherapy HDR-IRT Keloid POIRT

Journal

La Radiologia medica
ISSN: 1826-6983
Titre abrégé: Radiol Med
Pays: Italy
ID NLM: 0177625

Informations de publication

Date de publication:
27 Jan 2024
Historique:
received: 29 05 2023
accepted: 02 01 2024
medline: 28 1 2024
pubmed: 28 1 2024
entrez: 27 1 2024
Statut: aheadofprint

Résumé

To report the results involving post-operative interventional radiotherapy (POIRT) in a homogenous cohort of patients affected by keloid and treated at a single institution with the same fractionation schedule. Inclusion criteria were: surgery with a histopathological diagnosis of keloid, subsequent high-dose rate interventional radiotherapy (HDR-IRT)-12 Gy in 4 fractions (3 Gy/fr) twice a day-and follow-up period ≥ 24 months. One-hundred and two patients and a total of 135 keloids were eligible for the analyses. Median follow-up was 64 [IQR: 25-103] months. Thirty-six (26.7%) recurrences were observed, 12-months and 36-months cumulative incidence of recurrence were 20.7% (95% CI 12.2-28.5) and 23.8% (95% CI 14.9-31.7) respectively. History of spontaneous keloids (HR = 7.00, 95% CI 2.79-17.6, p < 0.001), spontaneous cheloid as keloid cause (HR = 6.97, 95% CI 2.05-23.7, p = 0.002) and sternal (HR = 10.6, 95% CI 3.08-36.8, p < 0.001), ear (HR = 6.03, 95% CI 1.71-21.3, p = 0.005) or limb (HR = 18.8, 95% CI 5.14-68.7, p < 0.001) keloid sites were significantly associated to a higher risk of recurrence. The findings support the use of surgery and POIRT as an effective strategy for controlling keloid relapses. Further studies should focus on determining the optimal Biologically Effective Dose and on establishing a scoring system for patient selection.

Identifiants

pubmed: 38280971
doi: 10.1007/s11547-024-01756-4
pii: 10.1007/s11547-024-01756-4
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s).

Références

Ogawa R (2017) Keloid and hypertrophic scars are the result of chronic inflammation in the reticular dermis. IJMS 18:606. https://doi.org/10.3390/ijms18030606
doi: 10.3390/ijms18030606 pubmed: 28287424 pmcid: 5372622
Huang J, Heng S, Zhang W et al (2022) Dermal extracellular matrix molecules in skin development, homeostasis, wound regeneration and diseases. Semin Cell Dev Biol 128:137–144. https://doi.org/10.1016/j.semcdb.2022.02.027
doi: 10.1016/j.semcdb.2022.02.027 pubmed: 35339360
Miller M-C, Nanchahal J (2005) Advances in the modulation of cutaneous wound healing and scarring. BioDrugs 19:363–381. https://doi.org/10.2165/00063030-200519060-00004
doi: 10.2165/00063030-200519060-00004 pubmed: 16392889
Baisch A, Riedel F (2006) Hyperplastische narben und keloide: teil I: grundlagen und prävention. HNO 54:893–905. https://doi.org/10.1007/s00106-006-1462-z
doi: 10.1007/s00106-006-1462-z pubmed: 17041777
Nakashima M, Chung S, Takahashi A et al (2010) A genome-wide association study identifies four susceptibility loci for keloid in the Japanese population. Nat Genet 42:768–771. https://doi.org/10.1038/ng.645
doi: 10.1038/ng.645 pubmed: 20711176
Marneros AG, Norris JEC, Watanabe S et al (2004) Genome scans provide evidence for keloid susceptibility loci on chromosomes 2q23 and 7p11. J Investig Dermatol 122:1126–1132. https://doi.org/10.1111/j.0022-202X.2004.22327.x
doi: 10.1111/j.0022-202X.2004.22327.x pubmed: 15140214
Betarbet U, Blalock TW (2020) Keloids: a review of etiology, prevention, and treatment. J Clin Aesthet Dermatol 13:33–43
pubmed: 32308783 pmcid: 7158916
Sequeira JH (1909) Case illustrating the effects of X-rays on scar-keloid. Proc R Soc Med 2:96–98
pubmed: 19973555 pmcid: 2046943
Ogawa R (2022) The most current algorithms for the treatment and prevention of hypertrophic scars and keloids: a 2020 update of the algorithms published 10 years ago. Plast Reconstr Surg 149:79e–94e. https://doi.org/10.1097/PRS.0000000000008667
doi: 10.1097/PRS.0000000000008667 pubmed: 34813576
De Cicco L, Vischioni B, Vavassori A et al (2014) Postoperative management of keloids: low-dose-rate and high-dose-rate brachytherapy. Brachytherapy 13:508–513. https://doi.org/10.1016/j.brachy.2014.01.005
doi: 10.1016/j.brachy.2014.01.005 pubmed: 24556345
Flickinger JC (2011) A Radiobiological analysis of multicenter data for postoperative keloid radiotherapy. Int J Radiat Oncol Biol Phys 79:1164–1170. https://doi.org/10.1016/j.ijrobp.2009.12.019
doi: 10.1016/j.ijrobp.2009.12.019 pubmed: 20472370
Lee JW, Seol KH (2021) Adjuvant radiotherapy after surgical excision in keloids. Medicina 57:730. https://doi.org/10.3390/medicina57070730
doi: 10.3390/medicina57070730 pubmed: 34357011 pmcid: 8306494
Chong Y, Long X, Ho Y-S (2021) Scientific landscape and trend analysis of keloid research: a 30-year bibliometric review. Ann Transl Med 9:945–945. https://doi.org/10.21037/atm-21-508
doi: 10.21037/atm-21-508 pubmed: 34350260 pmcid: 8263893
Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341–1346. https://doi.org/10.1016/0360-3016(95)00060-C
doi: 10.1016/0360-3016(95)00060-C pubmed: 7713792
Ying Z, Wei LJ (1994) The Kaplan-Meier estimate for dependent failure time observations. J Multivar Anal 50:17–29. https://doi.org/10.1006/jmva.1994.1031
doi: 10.1006/jmva.1994.1031
Jiang P, Baumann R, Dunst J et al (2016) Perioperative interstitial high-dose-rate brachytherapy for the treatment of recurrent keloids: feasibility and early results. Int J Radiat Oncol Biol Phys 94:532–536. https://doi.org/10.1016/j.ijrobp.2015.11.008
doi: 10.1016/j.ijrobp.2015.11.008 pubmed: 26867882
Bennett KG, Kung TA, Hayman JA, Brown DL (2017) Treatment of keloids with excision and adjuvant radiation: a single center experience and review of the literature. Ann Plast Surg 78:157–161. https://doi.org/10.1097/SAP.0000000000000903
doi: 10.1097/SAP.0000000000000903 pubmed: 27775986
Hafkamp CJH, Lapid O, Dávila Fajardo R et al (2017) Postoperative single-dose interstitial high-dose-rate brachytherapy in therapy-resistant keloids. Brachytherapy 16:415–420. https://doi.org/10.1016/j.brachy.2016.12.009
doi: 10.1016/j.brachy.2016.12.009 pubmed: 28139418
Bijlard E, Verduijn GM, Harmeling JX et al (2018) Optimal high-dose-rate brachytherapy fractionation scheme after keloid excision: a retrospective multicenter comparison of recurrence rates and complications. Int J Radiat Oncol Biol Phys 100:679–686. https://doi.org/10.1016/j.ijrobp.2017.10.044
doi: 10.1016/j.ijrobp.2017.10.044 pubmed: 29249529
Barragán VV, García AI, García JF, Marín MD, Vivas JD, Rijo GJ (2022) Perioperative interstitial high-dose-rate brachytherapy for keloids scar. J contemp brachytherapy 14(1):29–34. https://doi.org/10.5114/jcb.2022.113547
doi: 10.5114/jcb.2022.113547 pubmed: 35233232 pmcid: 8867237
Liao Y, Dorafshar AH, Bernard D et al (2022) High-dose-rate interstitial brachytherapy vs external beam radiation for the treatment of complex keloids. Med Dosim 47:158–160. https://doi.org/10.1016/j.meddos.2022.01.003
doi: 10.1016/j.meddos.2022.01.003 pubmed: 35264302
Zawadiuk LRR, Van Slyke AC, Bone J et al (2022) what do we know about treating recalcitrant auricular keloids? A systematic review and meta-analysis. Plast Surg (Oakv) 30:49–58. https://doi.org/10.1177/2292550321995746
doi: 10.1177/2292550321995746 pubmed: 35096693
Hsieh C-L, Chi K-Y, Lin W-Y, Lee LT-J (2021) Timing of adjuvant radiotherapy after keloid excision: a systematic review and meta-analysis. Dermatol Surg 47:1438–1443. https://doi.org/10.1097/DSS.0000000000003165
doi: 10.1097/DSS.0000000000003165 pubmed: 34417379
Noishiki C, Hayasaka Y, Ogawa R (2019) Sex differences in keloidogenesis: an analysis of 1659 keloid patients in Japan. Dermatol Ther (Heidelb) 9:747–754. https://doi.org/10.1007/s13555-019-00327-0
doi: 10.1007/s13555-019-00327-0 pubmed: 31586308
Park TH, Chang CH (2012) Keloid recurrence in pregnancy. Aesth Plast Surg 36:1271–1272. https://doi.org/10.1007/s00266-012-9947-5
doi: 10.1007/s00266-012-9947-5
Guix B, Henrı́quez I, Andrés A (2001) Treatment of keloids by high-dose-rate brachytherapy: A seven-year study. Int J Radiat Oncol Biol Phys 50:167–172. https://doi.org/10.1016/S0360-3016(00)01563-7
doi: 10.1016/S0360-3016(00)01563-7 pubmed: 11316560
Kal HB, Veen RE (2005) Biologically effective doses of postoperative radiotherapy in the prevention of keloids: dose-effect relationship. Strahlenther Onkol 181:717–723. https://doi.org/10.1007/s00066-005-1407-6
doi: 10.1007/s00066-005-1407-6 pubmed: 16254707
Dong W, Qiu B, Fan F (2022) Adjuvant radiotherapy for keloids. Aesth Plast Surg 46:489–499. https://doi.org/10.1007/s00266-021-02442-w
doi: 10.1007/s00266-021-02442-w
Renz P, Hasan S, Gresswell S et al (2018) Dose effect in adjuvant radiation therapy for the treatment of resected keloids. Int J Radiat Oncol Biol Phys 102:149–154. https://doi.org/10.1016/j.ijrobp.2018.05.027
doi: 10.1016/j.ijrobp.2018.05.027 pubmed: 29970316 pmcid: 7418482
Walsh LA, Wu E, Pontes D et al (2023) Keloid treatments: an evidence-based systematic review of recent advances. Syst Rev 12:42. https://doi.org/10.1186/s13643-023-02192-7
doi: 10.1186/s13643-023-02192-7 pubmed: 36918908 pmcid: 10012475

Auteurs

Jessica Franzetti (J)

Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Via Ripamonti, 435, 20141, Milan, Italy.
Department of Oncology and Hemato-Oncology, University of Milan, 20122, Milan, Italy.

Stefano Durante (S)

Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Via Ripamonti, 435, 20141, Milan, Italy.

Federico Mastroleo (F)

Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Via Ripamonti, 435, 20141, Milan, Italy. federico.mastroleo@ieo.it.
Department of Translational Medicine, University of Piemonte Orientale (UPO), 28100, Novara, Italy. federico.mastroleo@ieo.it.

Stefania Volpe (S)

Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Via Ripamonti, 435, 20141, Milan, Italy.
Department of Oncology and Hemato-Oncology, University of Milan, 20122, Milan, Italy.

Francesca De Lorenzi (F)

Department of Plastic and Reconstructive Surgery, European Institute of Oncology, IRCCS, Via Ripamonti, 435, 20141, Milan, Italy.

Marco Rotondi (M)

Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Via Ripamonti, 435, 20141, Milan, Italy.
Department of Oncology and Hemato-Oncology, University of Milan, 20122, Milan, Italy.

Chiara Lorubbio (C)

Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Via Ripamonti, 435, 20141, Milan, Italy.
Department of Oncology and Hemato-Oncology, University of Milan, 20122, Milan, Italy.

Angelo Vitullo (A)

Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Via Ripamonti, 435, 20141, Milan, Italy.
Department of Oncology and Hemato-Oncology, University of Milan, 20122, Milan, Italy.

Samuele Frassoni (S)

Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy.

Vincenzo Bagnardi (V)

Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy.

Raffaella Cambria (R)

Unit of Medical Physics, European Institute of Oncology IRCCS, Milan, Italy.

Federica Cattani (F)

Unit of Medical Physics, European Institute of Oncology IRCCS, Milan, Italy.

Andrea Vavassori (A)

Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Via Ripamonti, 435, 20141, Milan, Italy.

Barbara Alicja Jereczek-Fossa (BA)

Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Via Ripamonti, 435, 20141, Milan, Italy.
Department of Oncology and Hemato-Oncology, University of Milan, 20122, Milan, Italy.

Classifications MeSH